Selecting patients with HER2-low breast cancer: Getting out of the tangle
Open Access
- 19 September 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 175, 187-192
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- HER2-Low Breast CancersAmerican Journal of Clinical Pathology, 2021
- Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.Journal of Clinical Oncology, 2021
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancernpj Breast Cancer, 2021
- How current assay approval policies are leading to unintended imprecision medicineThe Lancet Oncology, 2020
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib StudyJournal of Clinical Oncology, 2020
- Why Cohen’s Kappa should be avoided as performance measure in classificationPLOS ONE, 2019
- Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancerLaboratory Investigation, 2016
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections.Journal of Histochemistry & Cytochemistry, 1996
- Interrater Reliability of Auscultation of Breath Sounds Among Physical TherapistsPhysical Therapy, 1995